Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dupilumab · 1 trial · 1 indication
Proportion of patients alive and free of invasive mechanical ventilation
Proportion of patients with abnormal diffusing capacity for carbon monoxide (DLCO) and/or 6 minute walk testing 1 year after acute COVID-19 infection.
| Arm | Type | Description |
|---|---|---|
| Dupilimab | EXPERIMENTAL | Dupilimab: 600 mg, given as two 300 mg subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28. |
| Placebo | PLACEBO_COMPARATOR | Normal saline will be given as two one mL subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (1 mL) will be given on days 14 and 28. |
| Name | Type | Description |
|---|---|---|
| Dupilumab | BIOLOGICAL | Participants will receive a loading dose of dupilumab (600 mg, given as two 300 mg subcutaneous injections) on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28. |
| Placebo | DRUG | Normal Saline. |
Inclusion Criteria: * Male or female 18 years of age or older at the time of enrollment. * Patients hospitalized with a positive RT-PCR for SARS-CoV-2 within the last 14 days, with illness duration within the last 14 days, and evidence of moderate to severe COVID-19 infection as defined by NIH COVI...
Dupilumab is a monoclonal antibody being investigated for the treatment of hospitalized COVID-19 patients. It is currently in Phase 2 clinical development for this indication. The drug is being studied to evaluate its safety and efficacy in this patient population.
Dupilumab is being developed by Catalyst Pharmaceuticals, Inc., a company traded on the stock exchange under the ticker symbol CPRX. The company is conducting clinical research to assess the drug's potential in treating COVID-19.
Dupilumab is in Phase 2 clinical development for COVID-19. A Phase 2 clinical trial has been completed to evaluate the drug's safety and efficacy in hospitalized patients with the condition. The drug remains investigational and is not yet approved for this use.
Dupilumab has been studied in a Phase 2 clinical trial with the identifier NCT04920916, titled 'Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients'. This trial was completed in the United States and enrolled 40 adult participants.
Yes, Dupilumab is a monoclonal antibody. It is being evaluated as a potential treatment for COVID-19 in a Phase 2 clinical trial. The trial was a randomized, double-blind, placebo-controlled study involving hospitalized patients.